Research programme: cannabinoids therapies - Viramal
Latest Information Update: 24 Mar 2024
Price :
$50 *
At a glance
- Originator Viramal
- Class Anti-inflammatories; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pelvic inflammatory disorders
Most Recent Events
- 24 Mar 2024 Viramal has patent protection for drug delivery technologies (Viramal Website, March 2024)
- 28 Feb 2024 Preclinical trials in Pelvic inflammatory disorders in United Kingdom (Vaginal) prior to February 2024 (Viramal pipeline, February 2024)